1. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.

    Alzheimer Disease and Associated Disorders 30(1):1 (2016) PMID 26885819

    Amyloid positron emission tomography (PET) imaging is being investigated as a screening tool to identify amyloid-positive patients as an enrichment strategy for Alzheimer disease (AD) clinical trial enrollment. In a multicenter, phase 1b trial, patients meeting clinical criteria for prodromal or...
  2. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

    Alzheimer's & Dementia 11(9):1050 (2015) PMID 25457431

    In vivo imaging of amyloid burden with positron emission tomography (PET) provides a means for studying the pathophysiology of Alzheimer's and related diseases. Measurement of subtle changes in amyloid burden requires quantitative analysis of image data. Reliable quantitative analysis of amyloid...
  3. ENRICHMENT OF EARLY-STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

    Alzheimer's & Dementia 10(4):P263 (2014)

  4. OPTIMIZED, FULLY-AUTOMATED CLASSIFICATION OF AMYLOID-POSITIVE SUBJECTS BASED ON [18F]FLORBETAPIR PET SCANS

    Alzheimer's & Dementia 10(4):P708 (2014)

  5. CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS

    Alzheimer's & Dementia 10(4):P399 (2014)

  6. Amyloid PET screening results by APOE-ε4 status from a phase 1b clinical study of 221AD103 in people with prodromal to mild Alzheimer's disease

    Alzheimer's & Dementia 9(4):P291 (2013)

  7. Amyloid PET screening for enrollment into Alzheimer's disease clinical trials: An effective enrichment strategy in a phase 1b clinical trial

    Alzheimer's & Dementia 9(4):P249 (2013)

  8. Comparison of actigraphy and polysomnography to assess effects of zolpidem in a clinical research unit.

    Sleep Medicine 13(4):419 (2012) PMID 22317945

    This study sought to compare devices that use actigraphy for measuring sleep endpoints in the clinical research unit (CRU) and home environment. The abilities of polysomnography (PSG) and actigraphy monitors to detect drug effects in a CRU were also investigated. Eleven healthy subjects were rec...